A prospective comparison of direct renin inhibitor aliskiren and AT1 receptor blocker in hypertensive patients with chronic kidney disease(CKD).

A prospective comparison of direct renin inhibitor aliskiren and AT1 receptor blocker in hypertensive patients with chronic kidney disease(CKD). - A prospective comparison of direct renin inhibitor aliskiren and AT1 receptor blocker in hypertensive patients with chronic kidney disease(CKD).

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008615

Enrollment

100

Registered

2012-08-04

Start date

2012-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension Chronic kidney disease

Interventions

Direct renin inhibitor group: Patients are initially given 150-300 mg of aliskiren once daily for 24 weeks. ARB group: Patients are initially given standard dose of ARB once daily for 24 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Hypertensive patients with CKD G1-G4. 2. Patients who are already receiving antihypertensive therapy including ARB.

Exclusion criteria

Exclusion criteria: 1. CKD G5, or dialysis patients. 2. History of hypersensitivity to ARB and/or aliskiren. 3. Pregnant women and/or women who are suspect of pregnancy. 4. Patients taking cyclosporin and/or itraconazole. Patients with history of angioedema 5. Patients judged as inappropriate for the study.

Design outcomes

Primary

Measure	Time frame
1. BW, obesity, abdominal circumference 2. Clinical blood pressure 3. Home blood pressure 4. ABPM 5. Renal function (urinary protein/albumin/Cr excretion, BUN, eGFR, uric acid, L-FABP) 6. Vascular function(AI, ABI/baPWV), CAVI, FMD) 7. Sympathetic nerve activity 8. Glucose metabolism (FBS, HbA1C, IRI, HOMA-IR) 9. Lipid metabolism (TCHO, LDLC, HDLC, TG) 10.Endocrine (PRA, PAC, urinary aldosteron concentration, BNP) 11.Oxidative stress (h-s CRP, serum pentosidine)	—

Measure

Time frame

1. BW, obesity, abdominal circumference 2. Clinical blood pressure 3. Home blood pressure 4. ABPM 5. Renal function (urinary protein/albumin/Cr excretion, BUN, eGFR, uric acid, L-FABP) 6. Vascular function(AI, ABI/baPWV), CAVI, FMD) 7. Sympathetic nerve activity 8. Glucose metabolism (FBS, HbA1C, IRI, HOMA-IR) 9. Lipid metabolism (TCHO, LDLC, HDLC, TG) 10.Endocrine (PRA, PAC, urinary aldosteron concentration, BNP) 11.Oxidative stress (h-s CRP, serum pentosidine)

—

Countries

Japan

Contacts

Public ContactKouichi TAMURA

Yokohama City University School of Medicine Department of Cardiorenal Medicine

tamukou@med.yokohama-cu.ac.jp045-787-2635

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026